Neuropsychiatric conditions such as epilepsy and schizophrenia consist of debilitating symptoms that are difficult and stressful to manage, and significantly impoverish patient’s lives. The first tool in our suite is the Neurobrowser, an AI based software that cuts down the time it takes to analyse an EEG from 30 minutes to 20 to 30 seconds, with the same level of accuracy as a neurologist. Our second tool, GenMind, is a mobile application that uses voice and individual responses to detect and remotely track cognitive impairment, mood changes, and decline in motivation and social engagement in serious mental illnesses. Our tools enable personalized treatment adjustments for each and every patient while helping providers gain time for increased patient management.

Neuropsychiatric conditions such as epilepsy and schizophrenia consist of debilitating symptoms that are difficult and stressful to manage, and significantly impoverish patient’s lives. The first tool in our suite is the Neurobrowser, an AI based software that cuts down the time it takes to analyse an EEG from 30 minutes to 20 to 30 seconds, with the same level of accuracy as a neurologist. Our second tool, GenMind, is a mobile application that uses voice and individual responses to detect and remotely track cognitive impairment, mood changes, and decline in motivation and social engagement in serious mental illnesses. Our tools enable personalized treatment adjustments for each and every patient while helping providers gain time for increased patient management.

The clinical insights and validation from Mayo Clinic and ASU, alongside the incredible wealth of information provided by subject matter experts, has been invaluable for refining what we do and how we should deliver our products in the US. We have gained a deeper insight into regulatory practices in the FDA as well as the innovation and resources we can tap into at both Mayo and ASU.

"Our participation in the MedTech accelerator has allowed us to interact with the Mayo Clinic and ASU family and its wealth of resources. We look forward to a continued long term collaboration with Mayo Clinic and ASU and together continue to achieve the mission of providing impact in healthcare."

Michel Birnbaum
CEO & Co-Founder, Mindsigns Health